# FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

> **NCT05069935** · PHASE1 · TERMINATED · sponsor: **Fate Therapeutics** · enrollment: 16 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** FT538
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **COMBINATION_PRODUCT:** Monoclonal antibody - Dose Escalation
- **COMBINATION_PRODUCT:** Monoclonal antibody - Dose Expansion

## Key facts

- **NCT ID:** NCT05069935
- **Lead sponsor:** Fate Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-15
- **Primary completion:** 2023-08-11
- **Final completion:** 2023-08-11
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** This study was terminated by the Sponsor.
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05069935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05069935, "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05069935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*